肝脏 ›› 2020, Vol. 25 ›› Issue (6): 582-584.

• 肝功能衰竭 • 上一篇    下一篇

血清p62及LC3-Ⅱ联合检测对HBV-ACLF患者近期预后的价值

刘铁峰, 许澍妮, 吴姗姗   

  1. 110032 沈阳 辽宁中医药大学附属医院检验科(刘铁峰, 吴姗姗);
    沈阳市中心血站检验科(许澍妮)
  • 出版日期:2020-06-30 发布日期:2020-07-16
  • 基金资助:
    辽宁省自然科学基金指导计划项目(20170540595)

Predictive value of combined detection of serum p62 and LC3-II for short-term prognosis of patients with hepatitis B virus related acute-on-chronic liver failure

LIU Tie-feng, XU Shu-ni, WU Shan-shan   

  1. Laboratory Department, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China
  • Online:2020-06-30 Published:2020-07-16

摘要: 目的 探讨血清自噬相关蛋白[p62和微管相关蛋白1轻链3-Ⅱ(LC3-Ⅱ)]联合检测在预测乙型肝炎病毒相关慢加急性肝衰竭(HBV-ACLF)患者近期预后中的应用价值。方法 收集2016年9月至2018年9月在辽宁中医药大学附属医院就诊的HBV-ACLF患者78例(ACLF组), 另选取同期健康体检者42名作为对照组。两组均采集清晨空腹静脉血, 测定总胆红素(TBil)、肌酐(Cr)和国际标准化比值(INR), 计算终末期肝病模型(MELD)分值;使用酶联免疫吸附法(ELISA)测定患者血清中p62和LC3-Ⅱ水平;记录患者入院后3个月内临床结局;应用受试者工作特征(ROC)曲线评价血清p62、LC3-Ⅱ预测HBV-ACLF患者近期预后的效力。结果 ACLF组血清LC3-Ⅱ水平明显高于对照组[(68.35±16.07)ng/mL比(37.96±11.50)ng/mL], p62水平低于对照组[(2.30±1.45)ng/mL比(4.63±2.38)ng/mL], 差异均有统计学意义(均P<0.05);Pearson相关分析显示, 血清p62与MELD评分呈负相关(r=0.383, P<0.05), 血清LC3-Ⅱ与MELD评分呈正相关(r=0.458, P<0.05);通过ROC曲线确定p62、LC3-Ⅱ预测HBV-ACLF患者近期预后的最佳临界值分别为1.51 ng/mL、80.74 ng/mL, 二者联合预测的AUC[0.813(95% CI:0.710~0.892)]分别大于p62[0.727(95% CI:0.616~0.821)], LC3-Ⅱ[0.736(95% CI:0.626~0.828)]单项预测的AUC, 差异均有统计学意义(均P<0.05), 而p62与LC3-Ⅱ预测HBV-ACLF预后的AUC差异无统计学意义(P>0.05)。结论 血清p62与LC3-Ⅱ在HBV-ACLF患者短期预后预测中具有一定价值, 二者联合检测能提高预后预测效力。

关键词: p62, 微管相关蛋白1轻链3-Ⅱ, 乙型肝炎相关慢加急性肝衰竭, 预后

Abstract: Objective To investigate theapplication value of combined detection of serum autophagy-associated proteins [p62 and microtubule-associated protein 1 light chain 3-II (LC3-II)] in predicting short-term prognosis of patients with hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF).Methods A total of 78 HBV-ACLF patients (ACLF group) admitted to our hospital from September 2016 to September 2018 were enrolled. And 42 healthy people who underwent physical examination in the same period were enrolled as control group. Fasting venous blood in the morning of both groups was collected. Total bilirubin, creatinine and international normalized ratio were measured. The scores of the model for end-stage liver disease (MELD) were calculated. Enzyme-linked immunosorbent assay was applied to measure levels of serum p62 and LC3-II. The clinical outcomes within 3 months after admission were recorded. The receiver operating characteristic (ROC) curves were applied to evaluate predicting efficiency of serum p62 and LC3-II for prognosis of HBV-ACLF patients.Results The level of serum LC3-II in ACLF group was significantly higher than that in control group [(68.35±16.07) ng/ml vs (37.96±11.50) ng/ml], while p62 level was lower than that in control group [(2.30±1.45) ng/ml vs (4.63±2.38) ng/ml] (P< 0.05). The results of Pearson correlation analysis showed that serum p62 was negatively correlated with MELD score (r=-0.383, P< 0.05), while serum LC3-II was positively correlated with MELD score (r=0.458, P< 0.05). ROC curves confirmed that optimal cut-off values of p62 and LC3-II for predicting short-term prognosis of HBV-ACLF patients were 1.51 ng/ml and 80.74 ng/ml, respectively. The area under the ROC curve (AUC) of their combined prediction was greater than that of p62 or LC3-II alone [0.813 (95% confidence interval: 0.710-0.892) vs 0.727 (95% confidence interval: 0.616-0.821), 0.736 (95% confidence interval: 0.626-0.828)] (P< 0.05). There was no significant difference in AUC between p62 and LC3-II for predicting prognosis of HBV-ACLF (P>0.05).Conclusion There is certain value of serum p62 and LC3-II in predicting short-term prognosis of patients with HBV-ACLF. The combined detection has better predictive value.

Key words: p62, Microtubule-associated protein 1 light chain 3-II, Hepatitis B virus related acute-on-chronic liver failure, Prognosis